Jump to content

Pulmocide: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
HomersDoh (talk | contribs)
243 edits
m Company logo added
m add {{Use dmy dates}}
 
(22 intermediate revisions by 11 users not shown)
Line 1: Line 1:
{{Use dmy dates|date=April 2022}}
{{Orphan|date=October 2020}}

{{Infobox company
{{Infobox company
| name = Pulmocide
| name = Pulmocide
| logo= Pulmocide_Company_Logo.jpg
| logo= Pulmocide_Company_Logo.jpg
| image =
| image =
| type = [[Privately held company|Privately held company]]
| type = [[Privately held company]]
| industry = [[Biopharmaceutical|Biopharmaceutical Research]], [[Medicine|Medical]], [[Drug discovery|Drug Discovery]]
| industry = [[Biopharmaceutical|Biopharmaceutical Research]], [[Medicine|Medical]], [[Drug discovery|Drug Discovery]]
| founded = {{Start date and age|2007|1}}
| founded = {{Start date and age|2007|1}}
| founders =
| founders =
| location =
| location = [[Imperial College London]]
| location_city = [[London]]
| location_country = [[United Kingdom]]
| location_country = [[United Kingdom]]
| area_served = [[European Union]]
| area_served = [[European Union]]
| key_people = Garth Rapeport, ([[CEO]])<br>Peter Strong ([[Chief scientific officer|CSO]])
| key_people = Garth Rapeport, ([[CEO]])<br />Peter Strong ([[Chief scientific officer|CSO]])
| website = {{URL|pulmocide.com}}
| website = {{URL|pulmocide.com}}
}}
}}
'''Pulmocide''' is a privately held [[Biopharmaceutical|biopharmaceutical]] company focusing on the discovery and development of inhaled [[Medicine|medicine]] for the treatment of life-threatening fungal and [[Viral disease|viral infections]] of the [[Respiratory tract|respiratory tract]].<ref>{{cite web|url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapid=251873006|title=Company Overview of Pulmocide Ltd|publisher=Bloomberg|accessdate=13 June 2019}}</ref> The company is based in [[London]].
'''Pulmocide''' is a privately held [[biopharmaceutical]] company focusing on the discovery and development of inhaled [[medicine]] for the treatment of life-threatening [[Mycosis|fungal]] and [[Viral disease|viral infections]] of the [[respiratory tract]].<ref>{{cite web|url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapid=251873006|title=Company Overview of Pulmocide Ltd|publisher=Bloomberg|accessdate=13 June 2019}}</ref> The company is based in [[London]] and has a laboratory at the [[Imperial College London|Imperial College’s]] Innovation Hub.<ref>{{cite web|url=https://www.telegraph.co.uk/business/2017/03/20/british-biotech-pulmocide-raises-24m-bid-find-treatment-deadly/|title=British biotech Pulmocide raises £24m in bid to find treatment for deadly lung diseases|publisher=The Telegraph|date=20 March 2017|accessdate=13 June 2019}}</ref>


==History==
==History==
Pulmocide was formed in 2007 by Garth Rapeport (CEO) and Pete Strong (CSO) who previously co-founded RespiVert Ltd alongside [[Peter J. Barnes (respiratory scientist)|Peter J. Barnes]] and Kazuhiro Ito.<ref name=AA>{{cite web|url=http://www.pharmatimes.com/news/j_and_j_buys_uk_biotech_respivert_983156|title=J&J buys UK biotech RespiVert|publisher=PharmaTimes|accessdate=13 June 2019}}</ref> RespiVert was acquired by a division of [[Johnson & Johnson|Johnson & Johnson]] in 2010.<ref name=AA/>
Pulmocide was formed in 2007 by Garth Rapeport ([[Chief executive officer|CEO]]) and Pete Strong ([[Chief scientific officer|CSO]]) who previously co-founded RespiVert Ltd alongside [[Peter J. Barnes (respiratory scientist)|Peter J. Barnes]] and Kazuhiro Ito.<ref name=AA>{{cite web|url=http://www.pharmatimes.com/news/j_and_j_buys_uk_biotech_respivert_983156|title=J&J buys UK biotech RespiVert|publisher=PharmaTimes|date=1 June 2010|accessdate=13 June 2019}}</ref> RespiVert was acquired by a division of [[Johnson & Johnson]] in 2010.<ref name=AA/>


In March 2017, Pulmocide raised $30 million in Series B Financing. The round was led by SR One and included Longwood Fund, SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation and Touchstone Innovations plc.<ref>{{Cite web|url=http://www.finsmes.com/2017/03/pulmocide-raises-30m-in-series-b-financing.html|title=Pulmocide Raises $30M in Series B Financing|last=FinSMEs|date=2017-03-21|website=FinSMEs|language=en-US|access-date=2020-03-12}}</ref>
==Drugs==

⚫
Pulmocide is conducting phase 2 trials with PC945, a potent inhaled antifungal agent for the treatment of [[Aspergillus|Aspergillus]] infections of the lung in patients with [[Asthma|asthma]], [[Cystic fibrosis|cystic fibrosis]] or following [[Lung transplantation|lung transplantation]].<ref name=AB>{{cite web|url=https://clinicaltrials.gov/ct2/show/NCT03382431|title=A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study|publisher=Clinicaltrials.gov|accessdate=13 June 2019}}</ref> Positive initial efficacy data for PC945 in treatment refractory Aspergillus infection following lung transplantation is reported.<ref>{{cite web|url=https://beam-alliance.eu/fungal-update-meeting-2019-first-case-report-of-pc945-treatment-of-refectory-aspergillus-anastomotic-infection-in-a-lung-transplant-recipient/|title=Fungal Update Meeting 2019: First Case Report of PC945 Treatment of Refectory Aspergillus Anastomotic Infection in a Lung Transplant Recipient|publisher=BEAM Alliance|accessdate=13 June 2019}}</ref> Pulmocide is conducting a study with PC786, an antiviral compound for the treatment of [[Human orthopneumovirus|Human orthopneumovirus]], formerly Human respiratory syncytial virus (HRSV).<ref name=AB/>
==Drug development==
⚫
Pulmocide is conducting phase 2 [[Clinical trial|trials]] with PC945, a potent inhaled [[antifungal]] agent for the treatment of [[Aspergillus]] infections of the lung in patients with [[asthma]], [[cystic fibrosis]] or following [[lung transplantation]].<ref name=AB>{{cite web|url=https://clinicaltrials.gov/ct2/show/NCT03382431|title=A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study|publisher=Clinicaltrials.gov|date=22 December 2017|accessdate=13 June 2019}}</ref> Positive initial efficacy data for PC945 in treatment refractory [[Aspergillus|Aspergillus infection]] following lung transplantation is reported.<ref>{{cite web|url=https://beam-alliance.eu/fungal-update-meeting-2019-first-case-report-of-pc945-treatment-of-refectory-aspergillus-anastomotic-infection-in-a-lung-transplant-recipient/|title=Fungal Update Meeting 2019: First Case Report of PC945 Treatment of Refectory Aspergillus Anastomotic Infection in a Lung Transplant Recipient|publisher=BEAM Alliance|date=19 March 2019|accessdate=13 June 2019}}</ref> Pulmocide is conducting a study with PC786, an antiviral compound for the treatment of [[Human orthopneumovirus]], formerly Human respiratory syncytial virus (HRSV).<ref name=AB/> A recent [[In silico|in-silico]] study on PC786 has been published in [[Science Advances|Science Advances, AAAS]],<ref>{{Cite journal|last=Panda|first=Pritam Kumar|last2=Arul|first2=Murugan Natarajan|last3=Patel|first3=Paritosh|last4=Verma|first4=Suresh K.|last5=Luo|first5=Wei|last6=Rubahn|first6=Horst-Günter|last7=Mishra|first7=Yogendra Kumar|last8=Suar|first8=Mrutyunjay|last9=Ahuja|first9=Rajeev|date=July 2020|title=Structure-based drug designing and immunoinformatics approach for SARS-CoV-2|url= |journal=Science Advances|language=en|volume=6|issue=28|pages=eabb8097|doi=10.1126/sciadv.abb8097|issn=2375-2548|pmc=7319274|pmid=32691011}}</ref> that showed improved binding efficacy<ref>{{Cite web|title=Computer screens antiviral compounds against coronavirus|url=https://www.natureasia.com/en/nindia/article/10.1038/nindia.2020.100|access-date=2020-10-20|website=Nature India|doi=10.1038/nindia.2020.100}}</ref> against the [[Severe acute respiratory syndrome coronavirus 2]].

In July 2019, Pulmocide announced a Scientific Reports (Nature Research) publication showing PC945 in combination with standard antifungal treatment causes a synergistic effect against Aspergillus fumigatus.<ref>{{cite web|url=http://www.biotechgate.com/web/cms/index.php/company_news_article.html?news_id=17533751k$SnFW1yNODg2yw&page_id=?next=1|title=Pulmocide announces Scientific Reports|publisher=Biotech Gate|date=2 July 2019|accessdate=8 July 2019}}</ref>


==References==
==References==
{{reflist}}
{{reflist}}

==External links==
{{Official website|pulmocide.com}}

[[Category:Organisations associated with Imperial College London]]
[[Category:Pharmaceutical companies established in 2007]]

Latest revision as of 08:55, 10 April 2022

Pulmocide
Company typePrivately held company
IndustryBiopharmaceutical Research, Medical, Drug Discovery
FoundedJanuary 2007; 18 years ago (2007-01)
HeadquartersImperial College London,
United Kingdom
Area served
European Union
Key people
Garth Rapeport, (CEO)
Peter Strong (CSO)
Websitepulmocide.com

Pulmocide is a privately held biopharmaceutical company focusing on the discovery and development of inhaled medicine for the treatment of life-threatening fungal and viral infections of the respiratory tract.[1] The company is based in London and has a laboratory at the Imperial College’s Innovation Hub.[2]

History

[edit]

Pulmocide was formed in 2007 by Garth Rapeport (CEO) and Pete Strong (CSO) who previously co-founded RespiVert Ltd alongside Peter J. Barnes and Kazuhiro Ito.[3] RespiVert was acquired by a division of Johnson & Johnson in 2010.[3]

In March 2017, Pulmocide raised $30 million in Series B Financing. The round was led by SR One and included Longwood Fund, SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation and Touchstone Innovations plc.[4]

Drug development

[edit]

Pulmocide is conducting phase 2 trials with PC945, a potent inhaled antifungal agent for the treatment of Aspergillus infections of the lung in patients with asthma, cystic fibrosis or following lung transplantation.[5] Positive initial efficacy data for PC945 in treatment refractory Aspergillus infection following lung transplantation is reported.[6] Pulmocide is conducting a study with PC786, an antiviral compound for the treatment of Human orthopneumovirus, formerly Human respiratory syncytial virus (HRSV).[5] A recent in-silico study on PC786 has been published in Science Advances, AAAS,[7] that showed improved binding efficacy[8] against the Severe acute respiratory syndrome coronavirus 2.

In July 2019, Pulmocide announced a Scientific Reports (Nature Research) publication showing PC945 in combination with standard antifungal treatment causes a synergistic effect against Aspergillus fumigatus.[9]

References

[edit]
  1. ^ "Company Overview of Pulmocide Ltd". Bloomberg. Retrieved 13 June 2019.
  2. ^ "British biotech Pulmocide raises £24m in bid to find treatment for deadly lung diseases". The Telegraph. 20 March 2017. Retrieved 13 June 2019.
  3. ^ a b "J&J buys UK biotech RespiVert". PharmaTimes. 1 June 2010. Retrieved 13 June 2019.
  4. ^ FinSMEs (21 March 2017). "Pulmocide Raises $30M in Series B Financing". FinSMEs. Retrieved 12 March 2020.
  5. ^ a b "A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study". Clinicaltrials.gov. 22 December 2017. Retrieved 13 June 2019.
  6. ^ "Fungal Update Meeting 2019: First Case Report of PC945 Treatment of Refectory Aspergillus Anastomotic Infection in a Lung Transplant Recipient". BEAM Alliance. 19 March 2019. Retrieved 13 June 2019.
  7. ^ Panda, Pritam Kumar; Arul, Murugan Natarajan; Patel, Paritosh; Verma, Suresh K.; Luo, Wei; Rubahn, Horst-Günter; Mishra, Yogendra Kumar; Suar, Mrutyunjay; Ahuja, Rajeev (July 2020). "Structure-based drug designing and immunoinformatics approach for SARS-CoV-2". Science Advances. 6 (28): eabb8097. doi:10.1126/sciadv.abb8097. ISSN 2375-2548. PMC 7319274. PMID 32691011.
  8. ^ "Computer screens antiviral compounds against coronavirus". Nature India. doi:10.1038/nindia.2020.100. Retrieved 20 October 2020.
  9. ^ "Pulmocide announces Scientific Reports". Biotech Gate. 2 July 2019. Retrieved 8 July 2019.
[edit]

Official website

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Pulmocide&oldid=1081892297"